Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License ...

Tivdak is a first-in-class therapy that combines an antibody target at tissue factor – a protein expressed on cervical cancer cells – with a cell-killing drug called monomethyl auristatin E.

Tivdak（tisotumab、替索单抗）是Seagen与Genmab A/S公司共同研发的一款靶向组织因子(TF)抗体和微管（Tubulin）抑制剂的药物偶联物(ADC)，于2021年9月获得美国FDA加速批准上市。Tivdak通过利用一种可被裂解的蛋白酶连接剂，将微管破坏剂MMAE（单甲基奥瑞他汀E）共价偶联在 ...

Tivdak Market Report 2025 The Business Research Company's Global Tivdak Market Outlook 2025-2034: Growth Drivers, Share, And Trends It will grow to $XX million in ...

Adding Seagen's four approved oncology drugs – Adcetris (brentuximab vedotin) for blood cancers, Padcev (enfortumab vedotin) for bladder cancer and cervical cancer therapy Tivdak (tisotumab ...

The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak ...

This ADC targets tissue factor (TF) and aims to improve upon the safety profile of existing treatments like Tivdak. Preclinical studies have shown promise for STRO-004 in TF-expressing lung and ...

1 Day ZLAB 0.39% DJIA 0.85% S&P 500 0.64% Health Care/Life Sciences -1.14% ...